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A 22-year-old female presented with back pain and was discovered to have a right-sided abdominal mass. Computed tomography
(CT) scan revealed a 9 cm enhancing right upper pole renal mass with suspicion for tumor thrombus into the right renal vein
and possibly the inferior vena cava (IVC). Magnetic resonance imaging (MRI) confirmed tumor thrombus into the inferior
vena cava approximately 3 cm below the hepatic venous confluence. Open right radical nephrectomy with inferior vena cava
thrombectomywas performedwith removal of right kidney and tumor thrombus en bloc. Pathology revealedmalignant epithelioid
angiomyolipoma (EAML or PEComa). Epithelioid angiomyolipoma is a rare tumor of mesenchymal tissue that has the potential
for local invasion and disease progression. Diagnosis of EAML was confirmed by pathology and immunohistochemistry. She
was referred to medical oncology for discussion of surveillance versus potential adjuvant therapy and ultimately opted for close
surveillance.
1. Introduction
EAML is a potentially malignant mesenchymal mass closely
related to angiomyolipoma and is composed of perivascu-
lar epithelioid, vascular, adipose, and smooth muscle cells.
EAML may be or is associated with tuberous sclerosis in
about 25% of cases. So far, only a small number of EAMLs
have been reported. Here we report the case of a 22-year-
old woman with a right-sided renal tumor and IVC tumor
thrombus that was confirmed as an EAML with intermediate
risk for progression by pathology.
2. Case Presentation
A 22-year-old female presented with back pain and her
primary care physician palpated a right-sided abdominal
mass. Family history was positive for renal cell carcinoma in
her grandmother diagnosed at the age of 63 years old but
was negative for tuberous sclerosis. Computed tomography
(CT) scan of the chest/abdomen/pelvis revealed a 8-9 cm
enhancing right upper pole renal mass with suspicion for
tumor thrombus into the renal vein and IVC (Figure 1).
There was no lymphadenopathy or pulmonary involvement.
Magnetic resonance imaging (MRI) confirmed aZincke Level
II venous tumor thrombus into the inferior vena cava to
approximately 3 cm below the hepatic venous confluence
(Figure 2).
Open right radical nephrectomywith IVC thrombectomy
was performed with removal of right kidney with mass and
tumor thrombus en bloc (Figure 3). Transplant surgery was
present and assisted with mobilization of the liver.
Her postoperative course was complicated by bilateral
pulmonary emboli. On postoperative day number two the
patient had tachycardia and tachypnea. CT PE protocol
revealed diffuse pulmonary emboli bilaterally. Systemic anti-
coagulation with a heparin drip was initiated and localized
infusion of tissue plasminogen activator (tPA) was per-
formed. The patient remained in the hospital until stable
from a cardiac and respiratory standpoint andwas discharged
home on oral anticoagulation with warfarin.




Figure 1: Axial images of computed tomography scan showing 9 cm
right upper pole mass.
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Figure 2: Coronal images of magnetic resonance imaging scan
showing tumor thrombus extending into inferior vena cava.
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Figure 3: Gross specimen after en bloc removal and then transec-
tion by pathologist.
Pathology revealed malignant epithelioid angiomyoli-
poma (PEComa), stage pT3bNx, Fuhrman grade IV. There
was 1–50% tumor necrosis and extensive lymphovascular
invasion, with involvement of the right renal vein and
inferior vena cava as noted above, as well as renal sinus and
perinephric fat invasion. Surgical margins were negative.The
patient was referred to medical oncology to discuss close
surveillance versus potential adjuvant chemotherapy. Based
on her pathology, she is at intermediate risk for disease
progression and ultimately chosen surveillance.
3. Discussion
Epithelioid angiomyolipomas (EAMLs) are a rare variant of
angiomyolipomas with the capability of recurrence and
metastasis. First reports of angiomyolipomas with epithelioid
morphology were in 1995 and 1996 [1, 2]. Whereas renal
angiomyolipomas are typically benign lesions, epithelioid
angiomyolipomas are potentially malignant. Renal AMLmay
sometimes show extension into the renal vein or IVC, but
this is thought to be multifocal growth rather than metastasis
[3]. Progressive enlargement and venous thrombosis are rare
complications [4] and involvement of regional lymph nodes
is uncommon [5]. AML is believed to belong to a family
of lesions, characterized by proliferation of perivascular
epithelioid cells. PEComas (tumors showing perivascular
epithelioid cell differentiation) are a family of related mes-
enchymal neoplasms that include AML, LAM, and clear cell
“sugar” tumor of the lung. There is a strong association
between PEComas and tuberous sclerosis, which is due to
the loss of tumor suppressor genes TSC1 or TSC2. Mutations
of p53 tumor suppressor gene may also play some role in
malignant transformation of EAMLs [6].
EAML is often confused with RCC on imaging. A typical
renal AML is suggested by renal masses that are markedly
hypoechoic relative to the renal parenchyma. Demonstration
of fat within the tumor on CT imaging is thought to confirm
the diagnosis [7]. Microscopically the presence of epithelioid
cells can make differentiating from RCC difficult without
immunohistochemistry.
EAML can only be definitively distinguished from benign
AML by immunohistochemistry. EAML will be negative for
cytokeratin and/or epithelialmembrane antigenmarkers, and
positive for one or more melanocytic markers and one or
more actin markers [8, 9]. A recent study by Aydin arbitrarily
qualified epithelioid tumors as containing at least 10% epithe-
lioid cells [9]. One recent study demonstrated that estrogen
receptor, PR, and bcl-2 markers were centered around dys-
morphic vessels and were expressed more significantly in
epithelioid AML variants [10].
Microscopically EAMLs are characterized by polygonal
cells with clear to eosinophilic cytoplasm and round to
oval nuclei that may show varying degree of nuclear atypia
[9]. Pure epithelioid PEComas have two major architectural
patterns: carcinoma like growth characterized by large cells
arranged in cohesive nests, broad alveoli, and compart-
mentalized sheets separated by thin vascular-rich septae
or epithelioid and plump spindle cells in diffuse growth
arranged in diffuse sheets [8].
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EAML is a potentially malignant variant of AML. A pre-
vious meta-analysis of 69 well-documented cases of EAML
showed that 38% were malignant [11]. Attempts have been
made to develop a risk stratification to determine progression
of malignancy of EAMLs based on five parameters: (1)
associated tuberous sclerosis complex, (2) necrosis, (3) tumor
size greater than 7 cm, (4) extrarenal extension and/or renal
vein involvement, and (5) carcinoma-like growth pattern.
Of these 5 parameters, carcinoma-like growth pattern and
extrarenal extension were the only reliable predictors of
outcome [8]. The same study found that of the 33 cases of
EAML studied, 10 of these had renal vein involvement, similar
to our patient. Another study of 40 cases of EAMLwith atypia
demonstrated several adverse histologic features associated
with malignancy: large epithelioid cell component, severe
nuclear atypia, extent of nuclear atypia, mitotic count, pres-
ence of atypical mitotic figures, necrosis, and the presence of
lymphovascular invasion [12].
To date there has been little documented about how to
treat the malignant version of EAML beyond excision.
Chemotherapy has shown mixed results. There is one case
report of doxorubicin reducing tumor size, but two other case
reports showing poor outcome with chemotherapy regimens
[13]. Kenerson et al. demonstrated that mTOR activation
was common to non-TSC-related AMLs and PEComas and
suggested that mTOR inhibitors such as rapamycin might
be a potential avenue for treatment [14]. Due to the rare
incidence of EAML, clinical trials to test this theory are
unlikely; however, there are several case reports showing that
rapamycin or other similar drugs may be clinically effective
in reducing tumor size [15, 16].
In summary, our patient presented with a right renal
mass with tumor thrombus into the renal vein and infe-
rior vena cava, with final pathology revealing epithelioid
angiomyolipoma. While rare, there have been several case
reports on this type of tumor. Due to the rarity of this disease,
there is currently a paucity of data regarding the need for
adjuvant therapy or the potential responsiveness of these
tumors to chemotherapy. Based on the current available data,
this patient will remain on a close surveillance protocol with
an intermediate risk of progression of disease. If she were
to progress, mTOR inhibitors are one potential therapeutic
option.
References
[1] K. T. Mai, D. G. Perkins, and J. P. Collins, “Epithelioid cell vari-
ant of renal angiomyolipoma,”Histopathology, vol. 28, no. 3, pp.
277–280, 1996.
[2] G. Martignoni, M. Pea, F. Bonetti et al., “Renal epithelioid oxy-
philic neoplasm (REON), a pleomorphic variant of renal angi-
omyolipoma,” International Journal of Surgical Pathology, vol. 2,
article 539, 1995.
[3] C. J. Davis, P. J. Woodward, L. P. Dehner et al., Pathology and
Genetics of Tumours of the Urinary System and Male Genital
Organs, IARC Press, Lyon, France, 2004.
[4] Y. Akcali, O. I. Karahan, G. Kahriman, H. Ceyran, and S. Balka-
nli, “Angiomyolipoma with cavoatrial extension,” European
Urology, vol. 50, no. 3, pp. 605–606, 2006.
[5] W.-Y. Lin, C.-K. Chuang, K.-F. Ng, and S.-K. Liao, “Renal angio-
myolipoma with lymph node involvement: a case report and
literature review,” Chang Gung Medical Journal, vol. 26, no. 8,
pp. 607–610, 2003.
[6] J. Li, M. Zhu, and Y. L. Wang, “Malignant epithelioid angiomy-
olipoma of the kidney with pulmonarymetastases and p53 gene
mutation,” World Journal of Surgical Oncology, vol. 10, article
213, 2012.
[7] T. Fro¨hlich, A. Brands,W. F.Thon, H.-P.Weskott, and H. Oster-
tag, “Angiomyolipoma of the kidney and lymph nodes,” World
Journal of Urology, vol. 17, no. 2, pp. 123–125, 1999.
[8] N. Nese, G. Martignoni, C. D. Fletcher et al., “Pure epithelioid
PEComas (so-called epithelioid angiomyolipoma) of the kid-
ney: a clinicopathologic study of 41 cases: Detailed assessment
of morphology and risk stratification,” American Journal of
Surgical Pathology, vol. 35, no. 2, pp. 161–176, 2011.
[9] H. Aydin, C. Magi-Galluzzi, B. R. Lane et al., “Renal angiomy-
olipoma: clinicopathologic study of 194 cases with emphasis
on the epithelioid histology and tuberous sclerosis association,”
American Journal of Surgical Pathology, vol. 33, no. 2, pp. 289–
297, 2009.
[10] N. H. Cho, H. S. Shim, Y. D. Choi, and D. S. Kim, “Estrogen
receptor is significantly associated with the epithelioid variants
of renal angiomyolipoma: a clinicopathological and immuno-
histochemical study of 67 cases,” Pathology International, vol.
54, no. 7, pp. 510–515, 2004.
[11] H. Faraji, B. N. Nguyen, and K. T. Mai, “Renal epithelioid
angiomyolipoma: a study of six cases and a meta-analytic study.
Development of criteria for screening the entity with prognostic
significance,” Histopathology, vol. 55, no. 5, pp. 525–534, 2009.
[12] F. Brimo, B. Robinson, C. Guo, M. Zhou, M. Latour, and J.
I. Epstein, “Renal epithelioid angiomyolipoma with atypia: a
series of 40 caseswith emphasis on clinicopathologic prognostic
indicators of malignancy,” American Journal of Surgical Pathol-
ogy, vol. 34, no. 5, pp. 715–722, 2010.
[13] E. S. Cibas, G. A. Goss, M. H. Kulke, G. D. Demetri, and C. D.
M. Fletcher, “Malignant epithelioid angiomyolipoma (’sarcoma
ex angiomyolipoma’) of the kidney: a case report and review of
the literature,” American Journal of Surgical Pathology, vol. 25,
no. 1, pp. 121–126, 2001.
[14] H. Kenerson, A. L. Folpe, T. K. Takayama, and R. S. Yeung,
“Activation of themTORpathway in sporadic angiomyolipomas
and other perivascular epithelioid cell neoplasms,” Human
Pathology, vol. 38, no. 9, pp. 1361–1371, 2007.
[15] N. Wolff, W. Kabbani, T. Bradley, G. Raj, L. Watumull, and J.
Brugarolas, “Sirolimus and temsirolimus for epithelioid angio-
myolipoma,” Journal of Clinical Oncology, vol. 28, no. 5, pp. e65–
e68, 2010.
[16] C. Gennatas, V. Michalaki, P. V. Kairi, A. Kondi-Paphiti, and
D. Voros, “Successful treatment with the mTOR inhibitor
everolimus in a patient with perivascular epithelioid cell tumor,”
World Journal of Surgical Oncology, vol. 10, article 181, 2012.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
